按疫苗接种来源比较mRNA疫苗对COVID-19相关住院的保护效果:免疫信息系统、电子病历与自我报告—IVY网络,2022年2月1日至8月31日
研究纳入2022年2月1日至8月31日美国18州21家医院IVY网络中≥18岁因COVID样疾病住院的4499例患者,比较免疫信息系统(IIS)、电子病历(EMR)和自我报告三种来源识别mRNA疫苗接种剂次的一致性及疫苗有效性(VE)估计差异。仅用EMR数据时3剂VE为31%(95%CI 16%-43%),低于合并所有来源的53%(95%CI 41%-62%),提示仅用EMR可能明显低估VE。
要点
- 自我报告识别≥1剂mRNA疫苗比例最高(3570例,79%),其次为IIS(3272例,73%)和EMR(3057例,68%)。
- 仅用EMR数据估计3剂VE为31%(95%CI 16%-43%),合并所有来源为53%(95%CI 41%-62%)。
- 仅使用EMR疫苗接种数据可能明显低估COVID-19疫苗有效性。
核心结论
- 仅使用EMR疫苗接种数据可能明显低估COVID-19疫苗有效性。
研究设计与样本
- 纳入2022年2月1日至8月31日在美国18个州21家医院IVY网络因COVID样疾病住院的≥18岁成人,共4499例患者。
- 采用kappa一致性分析比较IIS、EMR和自我报告识别的COVID-19疫苗接种剂次。
- 使用多变量logistic回归模型比较SARS-CoV-2阳性病例患者与SARS-CoV-2阴性对照患者的COVID-19疫苗接种比值,分别基于各单一来源及所有来源合并数据估计mRNA COVID-19疫苗对COVID-19相关住院的有效性。
主要发现
- 自我报告识别≥1剂mRNA COVID-19疫苗的患者最多(n=3570,79%),其次为IIS(n=3272,73%)和EMR(n=3057,68%)。
- IIS与自我报告对4剂识别的一致性最高,kappa为0.77(95%CI 0.73-0.81)。
- 仅使用EMR疫苗接种数据时3剂VE点估计为31%(95%CI 16%-43%),明显低于合并所有来源的53%(95%CI 41%-62%)。
临床怎么用
- 仅使用EMR疫苗接种数据可能明显低估COVID-19疫苗有效性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate determination of COVID-19 vaccination status is necessary to produce reliable COVID-19 vaccine effectiveness (VE) estimates. Data comparing differences in COVID-19 VE by vaccination sources (i.e., immunization information systems [IIS], electronic medical records [EMR], and self-report) are limited. We compared the number of mRNA COVID-19 vaccine doses identified by each of these sources to assess agreement as well as differences in VE estimates using vaccination data from each individual source and vaccination data adjudicated from all sources combined. METHODS: Adults aged ≥18 years who were hospitalized with COVID-like illness at 21 hospitals in 18 U.S. states participating in the IVY Network during February 1-August 31, 2022, were enrolled. Numbers of COVID-19 vaccine doses identified by IIS, EMR, and self-report were compared in kappa agreement analyses. Effectiveness of mRNA COVID-19 vaccines against COVID-19-associated hospitalization was estimated using multivariable logistic regression models to compare the odds of COVID-19 vaccination between SARS-CoV-2-positive case-patients and SARS-CoV-2-negative control-patients. VE was estimated using each source of vaccination data separately and all sources combined. RESULTS: A total of 4499 patients were included. Patients with ≥1 mRNA COVID-19 vaccine dose were identified most frequently by self-report (n = 3570, 79 %), followed by IIS (n = 3272, 73 %) and EMR (n = 3057, 68 %). Agreement was highest between IIS and self-report for 4 doses with a kappa of 0.77 (95 % CI = 0.73-0.81). VE point estimates of 3 doses against COVID-19 hospitalization were substantially lower when using vaccination data from EMR only (VE = 31 %, 95 % CI = 16 %-43 %) than when using all sources combined (VE = 53 %, 95 % CI = 41 %-62%). CONCLUSION: Vaccination data from EMR only may substantially underestimate COVID-19 VE.
引用
- Surie D, Bonnell LN, DeCuir J, et al. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. Vaccine. 2023. PMID: 37301704. doi:10.1016/j.vaccine.2023.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。